Mårten Fernö
121 – 130 of 256
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer - A national survey performed at pathology departments in Sweden.
(
- Contribution to journal › Article
-
Mark
Significantly higher expression of vascular endothelial growth factor (VEGF) and shorter survival after recurrences in premenopausal node negative patients with triple negative breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
Vascular endothelial growth factor receptor 2 is a significant negative prognostic biomarker in triple-negative breast cancer: results from a controlled randomised trial of premenopausal breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
Cyclin B1 Is an Independent Prognostic Proliferation Marker with a High Reproducibility in a Population-Based Lymph Node Negative Breast Cancer Cohort
(
- Contribution to journal › Published meeting abstract
-
Mark
Validation of the predictive value of tissue inhibitor of metalloproteinases-1 for the response to first-line chemotherapy in metastatic breast cancer.
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast conservation surgery with or without postoperative radiotherapy
(
- Contribution to journal › Article
-
Mark
Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays.
(
- Contribution to journal › Article
-
Mark
Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern.
(
- Contribution to journal › Article
-
Mark
HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
(
- Contribution to journal › Article
-
Mark
Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
(
- Contribution to journal › Article